InvestSMART

Atomo Diagnostics Limited (ASX:AT1)

ALERT: Price-sensitive ASX Announcement for AT1
Current share price for AT1 : $0.018 -0.021 (-53.85%)+
Announcement
Release
28 Jan 2026 9:53AM
Price at Release
$0.039
Full Release
download
Summary
Atomo Diagnostics Limited reported a strong quarter ending December 2025, with significant growth in revenue and cash flow management, resulting in $2.2 million in cash receipts primarily from customer sales and government grants. Revenue increased by 121% compared to the previous quarter, driven by orders in the HIV self-test and FebriDx Pascal products. The company secured significant international orders and further expanded its product portfolio by obtaining exclusive rights to a liver function test. Despite cash outflows of $2.1 million directed towards operational growth, Atomo ended the quarter with a healthy cash balance of $3.51 million and no debt, demonstrating tight control over operational expenses and a strategic focus on growth opportunities.
Key Points
  • Cash receipts for the quarter totaled $2.2m, including customer receipts and government grants.
  • The company had cash outflows of $2.1m, with a focus on program delivery and product supply.
  • Revenue for the quarter was $1.5m, marking a 121% growth from the previous quarter.
  • Atomo received orders totaling $495k for FebriDx Pascal and $500k for HIV Self-Test funded by the Global Fund.
  • Atomo secured an exclusive licensing agreement for a novel Liver function test.
  • Cash and cash equivalents at the end of the period were $3.51m, with no debt.
  • Operating expenses were tightly controlled, focusing on strategic growth opportunities.
  • The company is expanding its international market presence, particularly in Europe and Asia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.